NC
SWTX

nVerses Capital’s SpringWorks Therapeutics SWTX Stock Holding History

nVerses Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$4.92K – 1204
2024
Q1 		$4.92K Buy
+100
New +$4.62K 0.01% 588

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

nVerses Capital's SWTX Position: Q2 2024 in Review

nVerses Capital sold out of SpringWorks Therapeutics (SWTX) in Q2 2024, closing a stake of 100 shares — an estimated $4.92K sold.

nVerses Capital first reported a position in SWTX in Q1 2024 and held it in 1 quarter. The position peaked at $4.92K in Q1 2024. 209 funds tracked by Wall St. Rank hold SWTX as of Q2 2024.

  • nVerses Capital reported no remaining SpringWorks Therapeutics position as of Q2 2024 after selling out during the quarter.
  • nVerses Capital sold 100 SpringWorks Therapeutics shares in Q2 2024, an estimated $4.92K.
  • nVerses Capital first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 1 quarter.
  • nVerses Capital's SpringWorks Therapeutics position peaked at $4.92K in Q1 2024.
  • 209 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2024.

Based on nVerses Capital's 13F filing for Q2 2024, filed 31 Jul 2024.